These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32942128)

  • 1. Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy.
    Joo KI; Jeong Y; Hwang SM; Shin M; Lee J; Sharma G; Lee H; Im SH; Cha HJ
    Biomaterials; 2020 Dec; 263():120380. PubMed ID: 32942128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy.
    Chen Q; Sun M; Li Y; Huang L; Zu C; Kuang X; Zhao J; Hao M; Ma T; Li C; Tu J; Sun C; Du Y
    Nanomedicine; 2023 Sep; 53():102693. PubMed ID: 37343780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of immune checkpoint blockade in breast cancer.
    Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
    Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
    Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
    Front Immunol; 2022; 13():872295. PubMed ID: 35634282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade.
    Yu S; Wang C; Yu J; Wang J; Lu Y; Zhang Y; Zhang X; Hu Q; Sun W; He C; Chen X; Gu Z
    Adv Mater; 2018 Jul; 30(28):e1801527. PubMed ID: 29786888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma.
    Malo ME; Allen KJH; Jiao R; Frank C; Rickles D; Dadachova E
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
    Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
    Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
    Lee YH; Tai D; Yip C; Choo SP; Chew V
    Front Immunol; 2020; 11():568759. PubMed ID: 33117354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy.
    Huang J; Xiao Z; An Y; Han S; Wu W; Wang Y; Guo Y; Shuai X
    Biomaterials; 2021 Feb; 269():120636. PubMed ID: 33453632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
    de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
    Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes.
    Shan Z; Liu F
    Front Immunol; 2024; 15():1441410. PubMed ID: 39234260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA.
    Redmond WL; Kasiewicz MJ; Akporiaye ET
    Front Immunol; 2023; 14():1057702. PubMed ID: 36911733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
    Lu G; Qiu Y; Su X
    Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade.
    Chua KLM; Fehlings M; Yeo ELL; Nardin A; Sumatoh H; Chu PL; Nei WL; Ong EHW; Woo WY; Low KP; Wang H; Poon DJJ; Liang ZG; Yao K; Huang L; Toh CK; Ang MK; Farid M; Cheng XM; Kanesvaran R; Dent R; Wee JTS; Lim TKH; Iyer NG; Tan DSW; Soo KC; Newell EW; Chua MLK
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):70-80. PubMed ID: 32544576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
    Tambunlertchai S; Geary SM; Naguib YW; Salem AK
    AAPS J; 2023 Jun; 25(4):57. PubMed ID: 37266761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of melanoma with immune checkpoints inhibitors].
    Lupu J; Hamann P; Routier É; Robert C
    Rev Prat; 2021 Apr; 71(4):380-383. PubMed ID: 34161002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.